Core Insights - Immatics N.V. is advancing its PRAME cell therapy franchise with multiple high-impact milestones expected in 2026, including the progression of anzu-cel towards approval and the expansion of IMA203CD8 and IMA402 therapies [2][3] Company Progress - Anzu-cel (IMA203) is the lead PRAME cell therapy expected to enter the market for advanced melanoma, targeting an addressable patient population of approximately 9,000 [3] - The ongoing Phase 3 trial, SUPRAME, aims to evaluate the efficacy and safety of anzu-cel in previously treated advanced melanoma, with timelines for interim and final analyses expected in 2026 and a BLA submission planned for the first half of 2027 [6][7] - IMA203CD8, a second-generation PRAME cell therapy, is being developed to target all advanced PRAME cancers, with data updates expected in 2026 [8][12] - IMA402, a PRAME bispecific therapy, is being explored in combination with immune checkpoint inhibitors and is expected to have data updates in 2026 [9][13] Financial Results - As of December 31, 2025, the company reported cash and cash equivalents of $551.4 million (€469.3 million), a decrease from $710.3 million (€604.5 million) in 2024, primarily due to operational cash usage of $234.9 million (€199.9 million) [14] - Total revenue for the year ended December 31, 2025, was $56.8 million (€48.3 million), a significant decrease from $183.1 million (€155.8 million) in 2024, attributed to the termination of collaborations [15] - Research and development expenses increased to $216.0 million (€183.8 million) in 2025 from $174.0 million (€148.1 million) in 2024, reflecting ongoing clinical trial advancements [16] - The net loss for the year was $230.8 million (€196.4 million), compared to a net profit of $17.9 million (€15.2 million) in 2024, driven by lower revenue and increased R&D costs [18] Upcoming Developments - The company plans to present data updates from ongoing clinical trials at major medical conferences in 2026, focusing on ovarian cancer and other advanced PRAME cancers [12][13] - A collaboration with Moderna has been expanded, with the first patient dosed in a Phase 1 trial combining anzu-cel with Moderna's mRNA-4203, which is expected to enhance anti-tumor activity [11][12]

Core Insights - Immatics N.V. is advancing its PRAME cell therapy, anzu-cel, targeting advanced melanoma, with a focus on the ongoing SUPRAME Phase 3 trial as a top priority for market entry [2][3][7] - The company reported a significant decrease in total revenue for Q2 2025, amounting to $5.5 million, compared to $22.0 million in Q2 2024, primarily due to lower collaboration revenue [14] - Immatics has a strong cash position of $560.5 million as of June 30, 2025, which is expected to sustain operations into the second half of 2027 [6][13] Company Progress - Anzu-cel (IMA203) is set to be the first PRAME therapy to enter the market, targeting approximately 9,000 patients with advanced cutaneous melanoma and metastatic uveal melanoma [3][6] - The Phase 1b trial for anzu-cel demonstrated a clinical objective response rate (cORR) of 56% and a median duration of response (mDOR) of 12.1 months in heavily pretreated patients [6][7] - The SUPRAME trial is designed to evaluate anzu-cel against the investigator's choice in patients with unresectable or metastatic cutaneous melanoma, with primary endpoints focused on progression-free survival [7] Financial Results - Research and development expenses increased to $52.9 million for Q2 2025, up from $41.3 million in Q2 2024, reflecting ongoing clinical trial advancements [15] - The net loss for Q2 2025 was $82.4 million, compared to a net loss of $21.1 million in Q2 2024, attributed to lower revenue and higher unrealized foreign exchange losses [19] - General and administrative expenses rose to $15.0 million in Q2 2025, compared to $11.8 million in Q2 2024, indicating increased operational costs [18] Upcoming Developments - Immatics plans to provide updates on its next-generation PRAME bispecific, IMA402, and second-generation PRAME cell therapy, IMA203CD8, in the upcoming months [2][9] - A Phase 2 cohort for uveal melanoma is set to commence in Q4 2025, with data from the ongoing Phase 1b trial to be presented at the ESMO Congress 2025 [16] - The company is also developing IMA401, targeting MAGEA4/8, with updates expected in Q4 2025 [11][17]